Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pro-calcitonin for Early Detection of Septic Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02085733
Recruitment Status : Completed
First Posted : March 13, 2014
Last Update Posted : April 19, 2018
Sponsor:
Information provided by (Responsible Party):
Children's Hospitals and Clinics of Minnesota

Brief Summary:

Background:

Children presenting with non-traumatic joint pain require different treatment depending on the cause of pain. Septic arthritis, which results from a bacterial infection in the joint, often requires a surgical procedure as well as a long course of antibiotics. In contrast, non-septic arthritis is typically treated by management of symptoms and observation. Current diagnostic standards involve microbiologic examination of fluid taken from the affected joint. This procedure can require the patient to be sedated, and the fluid culture analysis can take up to 72 hours. A single laboratory measure that could be easily obtained and quickly analyzed would aid in faster diagnosis, fewer diagnostic tests and lower cost of the diagnostic work-up for this condition.

Recent research on septic arthritis has identified procalcitonin as a potential septic arthritis diagnostic indicator. Procalcitonin (PCT) is secreted by cells in the thyroid at higher levels when the body is facing infection. Procalcitonin levels rise slowly over the first two hours and peak at 24 hours. Levels rise 100-fold in the peripheral blood stream during this time frame. Several studies have indicated PCT is promising potential diagnostic indicator for septic arthritis. Unfortunately, many of these studies have relatively small sample sizes and very few involve pediatric populations. Additional study of PCT and septic arthritis in children will help evaluate the viability of PCT as a diagnostic indicator.

Research Question:

Can serum procalcitonin assist in clinical differentiation between bacterial (septic) and non-bacterial arthritis?

Methods:

Patients presenting with possible septic arthritis in the emergency department will be recruited for this study. Patients who consent to participate will receive the current standard for care, including IV placement, laboratory tests for Erythrocyte sedimentation rate (ESR),white blood cell count (WBC), and C-reactive protein (CRP), x-rays and consultation with pediatric orthopedics. Patients participating in the study will have a portion of the serum collected for typical diagnostic tests analyzed for PCT. Research assistants will collect data from medical records of participants, including lab and imaging results. Patients who do not undergo surgery will be contacted by phone within 7 days of their ED visit to confirm diagnosis.


Condition or disease
Arthritis, Infectious

Layout table for study information
Study Type : Observational
Actual Enrollment : 150 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Pro-calcitonin for Early Detection of Septic Arthritis
Study Start Date : February 2014
Actual Primary Completion Date : December 2016
Actual Study Completion Date : December 31, 2016

Resource links provided by the National Library of Medicine


Group/Cohort
Possible Septic Arhtritis Patients



Primary Outcome Measures :
  1. Septic Arthritis [ Time Frame: 7 days post ED visit ]
    The primary outcome will be the presence or absence of septic joint. We will confirm the presence of a septic joint by the growth of bacteria in the synovial fluid or presumed septic arthritis if any of the following three criteria are present: a) > 50,000 white cells in the synovial fluid, b) positive gram stain or c) positive blood culture in the setting of a swollen joint. For patients who do not undergo operative care, we will determine the presence or absence of septic joint by a templated follow-up telephone survey 7 days after enrollment. Patients who do not undergo an operative procedure will be presumed to have non-bacterial causes of their joint pain. Furthermore, culture negative synovial fluid or Lyme positive arthritis will be classified as non-bacterial causes of joint pain.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 16 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Emergency department patients.
Criteria

Inclusion Criteria:

  1. Are 0 - 16 years of age (inclusive)
  2. Have a painful, swollen, monoarticular joint
  3. Are suspected of having a septic joint
  4. Are able to provide assent and parents provide informed consent

Exclusion Criteria:

  1. Have reached anatomical maturity indicated by a closed physis in the joint of interest
  2. Have neuromuscular and/or metabolic disease
  3. Have a chromosomal disorder affecting chromosome 11 in the region of the CALC-1 gene
  4. Have received antibiotics within 7 days of the ED visit
  5. Are immune deficient
  6. Have had surgery in within the last 7 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02085733


Locations
Layout table for location information
United States, Minnesota
Children's Hospitals and Clinics of Minnesota
Minneapolis, Minnesota, United States, 55404
Sponsors and Collaborators
Children's Hospitals and Clinics of Minnesota
Investigators
Layout table for investigator information
Principal Investigator: Anupam B Kharbanda, MD, MSc Children's Minnesota

Layout table for additonal information
Responsible Party: Children's Hospitals and Clinics of Minnesota
ClinicalTrials.gov Identifier: NCT02085733     History of Changes
Other Study ID Numbers: 1311-107
First Posted: March 13, 2014    Key Record Dates
Last Update Posted: April 19, 2018
Last Verified: April 2018
Keywords provided by Children's Hospitals and Clinics of Minnesota:
Arthritis, Septic
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis, Infectious
Arthritis
Joint Diseases
Musculoskeletal Diseases
Infection
Calcitonin
Salmon calcitonin
Calcitonin Gene-Related Peptide
Katacalcin
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Bone Density Conservation Agents
Vasodilator Agents